 | Up a level |
2020
Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Lamanna, Nicole 
ORCID: 0000-0003-3331-9491, Kim, Su Young, Wu, Jenny, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn and Kater, Arnon
(2020).
Time-limited venetoclax-rituximab (VenR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): first presentation of 4-year data from the MURANO study.
Leuk. Lymphoma, 61.
S. 268 - 271.
ABINGDON:
TAYLOR & FRANCIS LTD.
ISSN 1029-2403
2019
Kater, Arnon P., Seymour, John F., Hillmen, Peter, Eichhorst, Barbara, Langerak, Anton W., Owen, Carolyn, Verdugo, Maria, Wu, Jenny, Punnoose, Elizabeth A., Jiang, Yanwen, Wang, Jue, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad and Kipps, Thomas J. (2019). Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J. Clin. Oncol., 37 (4). S. 269 - 287. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
2018
Kater, Arnon P., Hillmen, Peter, Eichhorst, Barbara, Langerak, Anton W., Kipps, Thomas J., Owen, Carolyn, Boyer, Michelle, Humphrey, Kathryn, Punnoose, Elizabeth A., Wang, Jue, Chyla, Brenda, Verdugo, Maria E., Wu, Jenny, Jiang, Yanwen, Mobasher, Mehrdad and Seymour, John F. (2018). First Prospective Data on Impact of Minimal Residual Disease on Long - Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020